

Review of: "[Research Note] Semaglutide, a GLP-1 Agonist Like Ozempic, and Its Potential Role as a Preventive Anti-Cancer Agent"

Andrea Brenna¹

¹ University of Fribourg

Potential competing interests: No potential competing interests to declare.

The title and abstract are misleading. Semaglutide is the chemical compound used as a GLP-1 agonist. Ozempic is the brand name. Therefore, the title needs to give a clear indication of what the main point the authors want to discuss is. For instance, they might compare Ozempic vs. Wegovy, two different brands selling the same drug. Otherwise, the title and abstract are not clear. The research note touches on many aspects, such as the inflammatory pathway and ROS, which is interesting. However, the language is too prosaic, which can distract readers. Please simplify the manuscript and highlight the key points.